Based on the financial data and recent analyst reports, here's a concise analysis of MET's valuation:
MetLife's current P/E ratio of 36.53 is significantly higher than its 2022 level of 11.48, suggesting potential overvaluation compared to historical levels.
The company's net income dropped substantially from $5.1B in 2022 to $1.38B in 2023, while EPS declined from $6.30 to $1.81, indicating deteriorating profitability metrics.
However, analysts remain bullish with a Strong Buy consensus and average price target of $98.18, representing a 20% upside from current levels.
The debt-to-equity ratio of 122.27% shows moderate leverage, though slightly improved from 131.56% in 2022, suggesting stable financial health.
The stock's current price of $81.70 appears overvalued based on deteriorating fundamentals, despite strong analyst sentiment and a healthy 6.84% dividend yield.